Panagora Asset Management Inc. trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,432 shares of the medical instruments supplier’s stock after selling 276 shares during the quarter. Panagora Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $3,031,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. DiNuzzo Private Wealth Inc. bought a new position in Becton, Dickinson and Company in the fourth quarter worth $30,000. Fortitude Family Office LLC purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $35,000. Venturi Wealth Management LLC boosted its stake in Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 138 shares in the last quarter. Arlington Trust Co LLC purchased a new stake in Becton, Dickinson and Company in the fourth quarter worth about $41,000. Finally, MCF Advisors LLC increased its stake in shares of Becton, Dickinson and Company by 51.4% during the fourth quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock valued at $52,000 after purchasing an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock. Becton, Dickinson and Company Trading Down 0.1 % Shares of NYSE BDX opened at $236.30 on Monday. The firm’s 50 day moving average price is $238.15 and its 200-day moving average price is $238.93. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The company has a market cap of $68.29 billion, a PE ratio of 52.05, a P/E/G ratio of 2.07 and a beta of 0.45. Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.86 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year. Becton, Dickinson and Company Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.61%. Becton, Dickinson and Company’s payout ratio is 83.70%. Wall Street Analyst Weigh In Separately, Barclays boosted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $281.40. Get Our Latest Research Report on BDX Insiders Place Their Bets In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,597 shares of company stock valued at $2,028,786. 0.31% of the stock is owned by insiders. Becton, Dickinson and Company Profile (Free Report) Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. Read More Five stocks we like better than Becton, Dickinson and Company 3 Small Caps With Big Return Potential JD’s Earnings Could Mean Chinese Stocks Making a Comeback Roth IRA Calculator: Calculate Your Potential Returns Canada Goose Flies Higher Driven By DTC Growth Insider Selling Explained: Can it Inform Your Investing Choices? CVS Health Stock Has a Silver Lining Called Value Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Meridian Wealth Management LLC decreased its position in MicroVision, Inc. (NASDAQ:MVIS – Free Report) by 50.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,605 shares of the electronics maker’s stock after selling 37,605 shares during the quarter. Meridian Wealth Management LLC’s holdings in MicroVision were worth $100,000 at the end of the most recent quarter. A number of other hedge funds also recently made changes to their positions in MVIS. Victory Capital Management Inc. increased its stake in MicroVision by 24.1% during the 4th quarter. Victory Capital Management Inc. now owns 25,355 shares of the electronics maker’s stock worth $67,000 after buying an additional 4,926 shares during the period. Cardinal Point Capital Management ULC grew its stake in MicroVision by 60.2% during the 4th quarter. Cardinal Point Capital Management ULC now owns 23,961 shares of the electronics maker’s stock valued at $64,000 after purchasing an additional 9,000 shares in the last quarter. Versor Investments LP purchased a new stake in MicroVision during the 3rd quarter worth approximately $25,000. Daiwa Securities Group Inc. raised its position in shares of MicroVision by 163.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 29,406 shares of the electronics maker’s stock valued at $78,000 after purchasing an additional 18,226 shares in the last quarter. Finally, MCF Advisors LLC boosted its stake in shares of MicroVision by 2.7% during the 4th quarter. MCF Advisors LLC now owns 1,009,746 shares of the electronics maker’s stock valued at $2,686,000 after buying an additional 27,000 shares during the last quarter. Hedge funds and other institutional investors own 30.90% of the company’s stock. MicroVision Stock Performance NASDAQ:MVIS opened at $1.15 on Monday. The company has a market capitalization of $237.66 million, a price-to-earnings ratio of -2.45 and a beta of 3.06. MicroVision, Inc. has a one year low of $1.12 and a one year high of $8.20. The stock has a 50-day simple moving average of $1.63 and a 200 day simple moving average of $2.13. MicroVision (NASDAQ:MVIS – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The electronics maker reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.96 million during the quarter. MicroVision had a negative net margin of 1,212.54% and a negative return on equity of 90.04%. During the same period last year, the business earned ($0.11) EPS. On average, equities research analysts forecast that MicroVision, Inc. will post -0.49 EPS for the current fiscal year. Analyst Ratings Changes Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $3.00 price target on shares of MicroVision in a report on Friday, March 1st. Check Out Our Latest Analysis on MVIS About MicroVision (Free Report) MicroVision, Inc develops and sells lidar sensors and software used in automotive safety and autonomous driving applications. It offers a suite of light detection and ranging (lidar) sensors and perception; and validation software for automotive OEMs, advanced driver-assistance systems, and autonomous vehicle applications, as well as non-automotive applications including industrial, robotics, and smart infrastructure. See Also Five stocks we like better than MicroVision What is Short Interest? How to Use It JD’s Earnings Could Mean Chinese Stocks Making a Comeback How Can Investors Benefit From After-Hours Trading Canada Goose Flies Higher Driven By DTC Growth Dividend Payout Ratio Calculator CVS Health Stock Has a Silver Lining Called Value

T. Rowe Price Group, Inc. (NASDAQ:TROW – Free Report) – Equities research analysts at Zacks Research raised their Q2 2024 earnings estimates for shares of T. Rowe Price Group in a report issued on Friday, May 17th. Zacks Research analyst R. Department now expects that the asset manager will post earnings per share of $2.02 for the quarter, up from their prior estimate of $1.99. The consensus estimate for T. Rowe Price Group’s current full-year earnings is $8.80 per share. Zacks Research also issued estimates for T. Rowe Price Group’s Q3 2024 earnings at $2.12 EPS, Q4 2024 earnings at $1.97 EPS, FY2024 earnings at $8.49 EPS, Q1 2025 earnings at $2.07 EPS, Q2 2025 earnings at $2.21 EPS, Q1 2026 earnings at $2.25 EPS and FY2026 earnings at $9.24 EPS. A number of other research analysts have also recently issued reports on TROW. Evercore ISI cut their price objective on T. Rowe Price Group from $110.00 to $107.00 and set an “in-line” rating for the company in a report on Tuesday, April 30th. TD Cowen raised shares of T. Rowe Price Group from a “sell” rating to a “hold” rating and lifted their price target for the company from $92.00 to $114.00 in a report on Monday, April 8th. UBS Group upped their price objective on shares of T. Rowe Price Group from $100.00 to $109.00 and gave the stock a “sell” rating in a research note on Friday, April 12th. Citigroup raised their price objective on shares of T. Rowe Price Group from $110.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, April 5th. Finally, Morgan Stanley increased their price target on T. Rowe Price Group from $114.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 17th. Four research analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $112.10. Get Our Latest Stock Analysis on T. Rowe Price Group T. Rowe Price Group Price Performance T. Rowe Price Group stock opened at $116.76 on Monday. The business has a 50 day simple moving average of $114.95 and a 200 day simple moving average of $108.89. The company has a market capitalization of $26.07 billion, a PE ratio of 13.87, a price-to-earnings-growth ratio of 2.02 and a beta of 1.40. T. Rowe Price Group has a one year low of $87.43 and a one year high of $132.76. T. Rowe Price Group (NASDAQ:TROW – Get Free Report) last announced its quarterly earnings results on Friday, April 26th. The asset manager reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.34. T. Rowe Price Group had a net margin of 29.09% and a return on equity of 19.70%. The firm had revenue of $1.75 billion during the quarter, compared to analysts’ expectations of $1.71 billion. During the same quarter last year, the company earned $1.69 earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. T. Rowe Price Group Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 4.25%. The ex-dividend date is Friday, June 14th. T. Rowe Price Group’s dividend payout ratio is 58.91%. Insiders Place Their Bets In other news, Director Robert F. Maclellan sold 3,043 shares of T. Rowe Price Group stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $113.08, for a total transaction of $344,102.44. Following the completion of the sale, the director now owns 34,635 shares in the company, valued at approximately $3,916,525.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other T. Rowe Price Group news, Director Freeman A. Hrabowski III sold 8,740 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $118.32, for a total transaction of $1,034,116.80. Following the transaction, the director now owns 21,073 shares in the company, valued at $2,493,357.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Robert F. Maclellan sold 3,043 shares of the company’s stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $113.08, for a total value of $344,102.44. Following the completion of the sale, the director now directly owns 34,635 shares of the company’s stock, valued at $3,916,525.80. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock. Institutional Trading of T. Rowe Price Group Large investors have recently bought and sold shares of the business. Massmutual Trust Co. FSB ADV raised its holdings in shares of T. Rowe Price Group by 7.5% during the first quarter. Massmutual Trust Co. FSB ADV now owns 1,236 shares of the asset manager’s stock worth $151,000 after acquiring an additional 86 shares during the period. ST Germain D J Co. Inc. raised its position in T. Rowe Price Group by 0.3% during the first quarter. ST Germain D J Co. Inc. now owns 31,065 shares of the asset manager’s stock worth $3,787,000 after acquiring an additional 88 shares in the last quarter. MCF Advisors LLC lifted its stake in T. Rowe Price Group by 1.6% in the first quarter. MCF Advisors LLC now owns 5,953 shares of the asset manager’s stock valued at $726,000 after acquiring an additional 92 shares during the last quarter. Paulson Wealth Management Inc. lifted its stake in T. Rowe Price Group by 4.9% in the first quarter. Paulson Wealth Management Inc. now owns 2,028 shares of the asset manager’s stock valued at $247,000 after acquiring an additional 95 shares during the last quarter. Finally, Clear Harbor Asset Management LLC grew its position in shares of T. Rowe Price Group by 3.2% in the 4th quarter. Clear Harbor Asset Management LLC now owns 3,240 shares of the asset manager’s stock valued at $349,000 after acquiring an additional 100 shares during the period. 73.39% of the stock is owned by institutional investors. T. Rowe Price Group Company Profile (Get Free Report) T. Rowe Price Group, Inc is a publicly owned investment manager. The firm provides its services to individuals, institutional investors, retirement plans, financial intermediaries, and institutions. It launches and manages equity and fixed income mutual funds. The firm invests in the public equity and fixed income markets across the globe.

Marvgallup Charitable Foundation is a non-profit organization that is also a subsidiary of Marvgallup Group Limited (founded in 2022). Marvgallup Charitable Foundation (MCF) strives to tackle hunger and poverty through sustainable enterprise. We desire to cater for the basic needs of those in disadvantaged positions, and we are wholly committed to our pledged service ... Read more The post Marvgallup Charitable Foundation Launches “She Is A Powerhouse” Initiative And Digital App appeared first...

Spartan Delta Corp.: Another Rollup In Progress

Contango Oil & Gas Appears To Have Reasonable Upside Now Despite Burdensome Hedges

Forget well-known companies and focus on this niche of the market.

Contango Oil & Gas: John Goff And Mr. Market Disagree

FORT WORTH, Texas, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) today announced the successful completion of its previously announced acquisition of low decline, conventional gas assets in the Wind River Basin of Wyoming from ConocoPhillips.

Contango Oil & Gas Company (MCF) CEO Wilkie Colyer on Q2 2021 Results - Earnings Call Transcript